文献速递认知障碍与谵妄多重用药老年综合评估

俄勒冈州辅助生活与寄宿照护居民的认知增强、抗精神病及阿片类药物使用情况

Cognition-Enhancing, Antipsychotic, and Opioid Medication Use Among Assisted Living and Residential Care Residents in Oregon.
PubMed 文献 · J Am Med Dir Assoc · 2021-01-28

本研究基于俄勒冈州387个持证社区中1135名辅助生活与寄宿照护(AL/RC)居民的横断面调查,描述了过去7天内认知增强药、抗精神病药和阿片类药物的使用比例,并分析居民与社区层面特征与用药的关联。结果显示约20%使用认知增强药,22%使用阿片类药,25%使用抗精神病药;农村地区阿尔茨海默病及相关痴呆(ADRD)居民使用认知增强药的可能性为城市居民的一半,ADRD居民使用抗精神病药的可能性约为非ADRD居民的3倍,使用阿片类药的可能性约为其一半。

要点

  • 约20%的AL/RC居民在过去7天使用认知增强药,22%使用阿片类药,25%使用抗精神病药。
  • 农村ADRD居民使用认知增强药的可能性为城市ADRD居民的一半。
  • 控制协变量后,ADRD居民使用抗精神病药的可能性约为非ADRD居民的3倍,使用阿片类药的可能性约为其一半。

核心结论

  • AL/RC居民中认知增强药、抗精神病药和阿片类药物的使用存在差异,ADRD诊断与农村居住与特定用药模式相关。

研究设计与样本

  • 横断面描述性研究,纳入俄勒冈州387个持证社区中1135名AL/RC居民,其中三分之一居住在提供痴呆记忆照护的社区。
  • 所有持证AL/RC社区接受邮寄调查,随机选取3名居民填写人口学、健康服务使用、健康状况、用药及支付信息。
  • 采用双变量和多因素logistic回归模型,估计居民和社区层面特征与各用药指标的未调整和调整比值比。

主要发现

  • 过去7天内,20%的居民使用认知增强药,22%使用阿片类药,25%使用抗精神病药(按计划或必要时使用)。
  • 居住在农村社区的ADRD居民使用认知增强药的可能性是城市ADRD居民的一半。
  • 控制所有居民和社区协变量后,ADRD居民接受抗精神病药的可能性约为非ADRD居民的3倍,接受阿片类药的可能性约为其一半。

临床怎么用

  • 在AL/RC环境中应关注ADRD居民抗精神病药使用可能偏高及阿片类药使用可能偏低的现象。
  • 农村ADRD居民认知增强药使用率较低,提示需关注农村地区痴呆治疗可及性。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Explore community- and resident-level characteristics associated with polypharmacy and use of cognition-enhancing, antipsychotic, and opioid medications among a statewide representative sample of assisted living and residential care (AL/RC) residents. DESIGN: Cross-sectional, descriptive. SETTING AND PARTICIPANTS: A total of 1135 AL/RC residents living in 387 licensed communities in Oregon were recruited. One-third of residents lived in communities certified to provide memory care to residents with dementia. METHODS: All licensed AL/RC communities received a mail survey with questions about 3 randomly selected residents' demographic, health service use, health conditions, medication use, and payment information. We estimated bivariate and multiple logistic regression models, resulting in unadjusted and adjusted odds ratios of resident- and community-level characteristics associated with each medication use indicator. RESULTS: One in 5 residents took a cognition-enhancing medication (20%) in the prior 7 days. Just more than one-fifth (22%) and one-quarter (25%) of residents took opioid or antipsychotic medications, on a scheduled or as-needed basis in the prior 7 days, respectively. Residents with Alzheimer's disease or related dementia (ADRD) living in rural communities were half as likely to take cognitive-enhancing medications compared with their urban counterparts. When controlling for all resident and community covariates, residents with ADRD were almost 3 times as likely to receive an antipsychotic and half as likely to receive an opioid compared to residents without an ADRD diagnosis. CONCLUSIONS AND IMPLICATIONS: Understanding variation in the use of medications associated with behavioral expressions of ADRD in AL/RC residents is a crucial clinical and policy area.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Dys S, Tunalilar O, Carder P, et al. Cognition-Enhancing, Antipsychotic, and Opioid Medication Use Among Assisted Living and Residential Care Residents in Oregon. J Am Med Dir Assoc. 2021. PMID: 33516674. doi:10.1016/j.jamda.2020.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。